Robert Stagg

4.3k citations

61 papers · 3.3k indexed · h-index 24

Impact in

Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment

Papers in ⓘ

Oncology 40
- Cancer Cells and Metastasis 15
- Pancreatic and Hepatic Oncology Research 11
- Cancer Treatment and Pharmacology 5
Hepatology 7
- Hepatocellular Carcinoma Treatment and Prognosis 7

Co-authors: B.J. Lewis (7 shared papers)Mark Kaminski (5 shared papers)George F. Tidmarsh (4 shared papers)Richard L. Wahl (4 shared papers)Ann M. Kapoun (17 shared papers)David C. Hohn (3 shared papers)Anthony A. Rayner (3 shared papers)Andrew D. Zelenetz (3 shared papers)
Journals: Journal of Clinical Oncology (17 papers)Molecular Cancer Therapeutics (5 papers)Gynecologic Oncology (4 papers)Cancer (3 papers)Clinical Cancer Research (3 papers)
Partner nations: United States Australia New Zealand

In The Last Decade

Robert Stagg

61 papers receiving 3.2k citations

Peers

Countries citing papers authored by Robert Stagg

Since Specialization

Citations

This map shows the geographic impact of Robert Stagg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Stagg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Stagg more than expected).

Fields of papers citing papers by Robert Stagg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Stagg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Stagg. The network helps show where Robert Stagg may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert Stagg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert Stagg Line = papers co-authored together Robert Stagg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas Journal of Clinical Oncology ·Mark Kaminski, Andrew D. Zelenetz, Oliver W. Press, Mansoor N. Saleh, John P. Leonard, Louis Fehrenbacher, T. Andrew Lister, Robert Stagg, George F. Tidmarsh, Stew Kroll, Richard L. Wahl, Susan J. Knox, Julie M. Vose	2001	442
2	Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood ·Mark Kaminski, Judith Estes, Kenneth Zasadny, Isaac R. Francis, Charles W. Ross, Melissa Tuck, Denise Regan, Susan J. Fisher, Jeanne Gutierrez, Stewart Kroll, Robert Stagg, George F. Tidmarsh, Richard L. Wahl	2000	400
3	A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. Journal of Clinical Oncology ·David C. Hohn, Robert Stagg, Michael Friedman, John F. Hannigan, Anthony A. Rayner, R Ignoffo, P Acord, B.J. Lewis	1989	349
4	Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas Journal of Clinical Oncology ·Julie M. Vose, Richard L. Wahl, Mansoor N. Saleh, A. Z. S. Rohatiner, Susan J. Knox, John Radford, Andrew D. Zelenetz, George F. Tidmarsh, Robert Stagg, Mark Kaminski	2000	273
5	A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Antonio Jimeno, Michael A. Gordon, Rashmi Chugh, Wells A. Messersmith, David S. Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Shailaja Uttamsingh, Rainer K. Brachmann, David C. Smith	2017	172
6	Chemoembolization for hepatocellular carcinoma. Journal of Clinical Oncology ·Alan P. Venook, Robert Stagg, B.J. Lewis, Judy L. Chase, Ernest J. Ring, Timothy P. Maroney, David C. Hohn	1990	124
7	A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors Clinical Cancer Research ·David C. Smith, Peter D. Eisenberg, Georgy M. Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, Branimir I. Šikić	2014	123
8	Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. Journal of Clinical Oncology ·D. Höhn, Joel Z. Melnick, Robert Stagg, Douglas G. Altman, Michael Friedman, R Ignoffo, Lee Ferrell, B.J. Lewis	1985	122
9	Cidofovir, a New Agent with Potent Anti-Herpesvirus Activity Antiviral chemistry & chemotherapy ·Michael J. M. Hitchcock, Howard S. Jaffe, John C. Martin, Robert Stagg	1996	110
10	Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion Cancer ·David C. Hohn, Anthony A. Rayner, James S. Economou, Robert J. Ignoffo, B.J. Lewis, Robert Stagg	1986	97
11	A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer Investigational New Drugs ·S. Lindsey Davis, Dana B. Cardin, Safi Shahda, Heinz‐Josef Lenz, Efrat Dotan, Bert H. O’Neil, Ann M. Kapoun, Robert Stagg, Jordan Berlin, Wells A. Messersmith, Steven J. Cohen	2019	80
12	A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer Gynecologic Oncology ·Kathleen N. Moore, Camille C. Gunderson, Paul Sabbatini, D. Scott McMeekin, Gina Mantia-Smaldone, Robert A. Burger, Mark A. Morgan, Ann M. Kapoun, Rainer K. Brachmann, Robert Stagg, Azeez Farooki, Roisin E. O’Cearbhaill	2019	79
13	Randomized, Controlled Study of the Safety and Efficacy of Intravenous Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Jacob Lalezari, Gary N. Holland, Françoise Kramer, George McKinley, Carol A. Kemper, David V. Ives, Robert G. Nelson, W. D. Hardy, Baruch D. Kuppermann, Donald W. Northfelt, M Youle, Margaret Johnson, Richard A. Lewis, David V. Weinberg, Gary L. Simon, Richard A. Wolitz, April Ruby, Robert Stagg, Howard S. Jaffe	1998	72
14	Alternating Hepatic Intra-Arterial Floxuridine and Fluorouracil: A Less Toxic Regimen for Treatment of Liver Metastases From Colorectal Cancer JNCI Journal of the National Cancer Institute ·Robert Stagg, Alan P. Venook, Judy L. Chase, B.J. Lewis, Robert S. Warren, Mark S. Roh, Sean J. Mulvihill, Barry Grobman, Anthony A. Rayner, David C. Hohn	1991	67
15	First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. Journal of Clinical Oncology ·David C. Smith, Lee S. Rosen, Rashmi Chugh, Jonathan W. Goldman, Lu Xu, Ann M. Kapoun, Ranier K Brachmann, Jakob Dupont, Robert Stagg, Anthony W. Tolcher, Kyriakos P. Papadopoulos	2013	66
16	A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors Investigational New Drugs ·Antonio Jimeno, Kathleen N. Moore, Michael S. Gordon, Rashmi Chugh, Jennifer R. Diamond, Raid Aljumaily, David S. Mendelson, Ann M. Kapoun, Lu Xu, Robert Stagg, David C. Smith	2018	61
17	Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer Clinical Cancer Research ·Efrat Dotan, Dana B. Cardin, Heinz‐Josef Lenz, Wells A. Messersmith, Bert H. O’Neil, Steven J. Cohen, Crystal S. Denlinger, Safi Shahda, Igor Astsaturov, Ann M. Kapoun, Rainer K. Brachmann, Shailaja Uttamsingh, Robert Stagg, Colin D. Weekes	2020	59
18	A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors Investigational New Drugs ·David C. Smith, Rashmi Chugh, Amita Patnaik, Kyriakos P. Papadopoulos, Min Wang, Ann M. Kapoun, Lu Xu, Jakob Dupont, Robert Stagg, Anthony W. Tolcher	2018	58
19	Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC Targeted Oncology ·Mark J. McKeage, Dusan Kotasek, Ben Markman, Manuel Hidalgo, Michael Millward, Michael B. Jameson, Dean Harris, Robert Stagg, Ann M. Kapoun, Lu Xu, Brett Hughes	2017	57
20	Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2'-deoxyuridine. Journal of Clinical Oncology ·David C. Hohn, Robert Stagg, David C. Price, B.J. Lewis	1985	54

About Robert Stagg

Robert Stagg is a scholar working on Oncology, Hepatology, Reproductive Medicine, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine, having authored 61 papers that have together received 3.3k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (15 papers), Lung Cancer Treatments and Mutations (11 papers), Pancreatic and Hepatic Oncology Research (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cancer Treatment and Pharmacology (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). The work is most often cited by research in Hepatology (705 citations), Pathology and Forensic Medicine (987 citations), Oncology (1.4k citations), Radiology, Nuclear Medicine and Imaging (947 citations) and Genetics (229 citations). Robert Stagg has collaborated with scholars based in United States, Australia and New Zealand. Frequent co-authors include B.J. Lewis, Mark Kaminski, George F. Tidmarsh, Richard L. Wahl, Ann M. Kapoun, David C. Hohn, Anthony A. Rayner, Andrew D. Zelenetz, Julie M. Vose and Mansoor N. Saleh. Their work appears in journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics, Gynecologic Oncology, Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact